Loading company
ONCBeone Medicines Ltd.$48BA+Built from Maravai LifeSciences Holdings, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
The themes Maravai LifeSciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
$7.70-2.1%Nov 11 close
Figures through September 30, 2026, from the 10-Q filed November 5, 2026
Company outlook: revenue of $205M to $215M for Fiscal year 2026 — up 13.1% on a year earlier
Grade D-
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 20 quarters of Maravai LifeSciences Holdings, Inc.’s grade history. The other 18 go back to March 2022.
